Cartesian Therapeutics (RNAC) Gains from Investment Securities (2015 - 2026)

Cartesian Therapeutics (RNAC) has 10 years of Gains from Investment Securities data on file, last reported at -$94000.0 in Q1 2026.

• On a quarterly basis, Gains from Investment Securities rose 94.83% year-over-year to -$94000.0 in Q1 2026; TTM through Mar 2026 was -$2.0 million, a 40.88% increase from a year earlier, with the FY2025 full-year figure at -$3.7 million, down 44.45% from the prior year.
• Gains from Investment Securities for Q1 2026 stood at -$94000.0, up from -$707000.0 in the prior quarter.
• Over the last five years, Gains from Investment Securities for RNAC reached as high as $6.5 million in Q3 2022 and fell as low as -$18.5 million in Q1 2022.
• Historically, Gains from Investment Securities has averaged -$2.4 million across 5 years, with a median of -$707000.0 in 2025.
• Across the five-year window, Gains from Investment Securities surged 1204.56% in 2022 and sank 388.57% in 2025, its largest moves.
• Year by year, Gains from Investment Securities stood at -$13.6 million in 2022, then surged by 50.59% to -$6.7 million in 2023, then surged by 103.66% to $245000.0 in 2024, then tumbled by 388.57% to -$707000.0 in 2025, then jumped by 86.7% to -$94000.0 in 2026.
• Per Business Quant data, the three most recent Gains from Investment Securities figures were -$94000.0 in Q1 2026, -$707000.0 in Q4 2025, and -$516000.0 in Q3 2025.